Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**") pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The board of directors (the "**Director(s)**") of the Company (the "**Board**") announces that in order to reflect the share capital of the Company after the listing of the Company's A shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange, the Board proposes to amend the relevant provisions of the articles of association of the Company (the "**Articles of Association**") (the "**Proposed Amendments to the Articles of Association**").

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The followings set forth the details of the proposed amendments:

Before amendment	After amendment
Article 4 After registration with the CSRC on [•], the Company issued [•] RMB-denominated ordinary A shares to the general public. On [•], it was officially listed on the STAR Market of the Shanghai Stock Exchange.	**Article 4** After registration with the CSRC on **October 15, 2025**, the Company issued **47,500,000** RMB-denominated ordinary A shares to the general public. On **December 10, 2025**, it was officially listed on the STAR Market of the Shanghai Stock Exchange.
Article 6 The registered capital of the Company is RMB[•].	**Article 6** The registered capital of the Company is RMB**446,898,420**.
Article 21 The total number of shares of the Company is [•] shares, all of which are ordinary shares.	**Article 21** The total number of shares of the Company is **446,898,420** shares, all of which are ordinary shares.

Before amendment	After amendment
Article 213 These Articles of Association shall take effect upon the approval of the Shareholders' General Meeting and on the date when the Company completes its initial public offering of A-shares and lists on the on the STAR Market of the SSE. From the effective date of these Articles of Association, the Company's original articles of association shall automatically become invalid.	**Article 213** These Articles of Association shall take effect upon the approval of the Shareholders' General Meeting ~~and on the date when the Company completes its initial public offering of A-shares and lists on the on the STAR Market of the SSE. From the effective date of these Articles of Association, the Company's original articles of association shall automatically become invalid~~.

The English version of the proposed amendments to the Articles of Association is an unofficial translation of its Chinese version. In case of any discrepancy between the two versions, the Chinese version shall prevail.

The Board believes that the Proposed Amendments to the Articles of Associations are in the interests of the Company and its shareholders (the "**Shareholders**").

GENERAL

The Company will convene the annual general meeting of the Company (the "**AGM**") for the purposes of, among other things, seeking the Shareholders' approval for the Proposed Amendments to the Articles of Association. The votes will be taken by poll at the AGM. The resolution is subject to the approval by the Shareholders by way of passing a special resolution at the AGM. A circular containing, among other things, details of the Proposed Amendments to the Articles of Associations, together with the notice of AGM, will be published on the website of the Stock Exchange (http://www.hkexnews.hk) and that of the Company (https://www.biocytogen.com.cn).

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, March 26, 2026

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian as executive Director; Dr. Liu Hongkang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors; and Ms. Li Yan as employee Director.